PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2011 Views
-
Last post by NHE
-
- 0 Replies
- 921 Views
-
Last post by NHE
-
- 0 Replies
- 9427 Views
-
Last post by NHE
-
- 0 Replies
- 1783 Views
-
Last post by Firidion
-
- 1 Replies
- 1289 Views
-
Last post by vesta
-
- 0 Replies
- 1948 Views
-
Last post by frodo
-
- 0 Replies
- 1874 Views
-
Last post by NHE
-
- 0 Replies
- 1411 Views
-
Last post by NHE
-
- 4 Replies
- 2339 Views
-
Last post by JohnC777